这是前不久的二则消息：给关心疫苗的朋友们转来看看：
Acambis says starts pre-clinical testing of herpes vaccine UPDATE February 25, 2008: 07:05 AM EST
(Adds analyst reaction)
LONDON, Feb. 25, 2008 (Thomson Financialdelivered by Newstex) -- UK vaccine specialist Acambis says it hasstarted pre-clinical testing of a vaccine for herpes, with a view tosubmitting an investigational new drug application in 2009.
There is currently no vaccine on the market for herpes, and the WorldHealth Organization (WHO) estimates that 40 to 60 million Americans areinfected, making the disease one of the most common STIs in the US,Acambis says.
The vaccine, which Acambis has licensed fromHarvard University, protects against the herpes virus strains whichcause both genital and oral herpes.
Chief executive Ian Garlandsaid: 'This is a very attractive programme for a major vaccine marketwith limited competition and we are delighted to have licensed thisHarvard Medical School technology.'
Shawn Manning at LandsbankiSecurities said, in a note to clients, that he was not adding thevaccine to his valuation for the company yet, given its early stage ofdevelopment.
He also pointed out that a number of vaccines arenow under development to prevent infection, led by GlaxoSmithKline's(NYSE:GSK) Phase III Simplirix, although the level of response in theAcambis vaccine could be greater than that observed in Simplirix.
He reiterated his 'Buy' stance on Acambis and 164 pence price target.
Copyright Thomson Financial News Limited 2007. All rights reserved.
Thecopying, republication or redistribution of Thomson Financial NewsContent, including by framing or similar means, is expressly prohibitedwithout the prior written consent of Thomson Financial News.
GenVec gets grant for herpes vaccine By Andrea K. Walker |Sun reporter11:58 AM EST, March 6, 2008 Gaithersburg drugmaker GenVec,Inc. said this morning that it has received a $600,000 two-year grantto help in its development of a vaccine to treat genital herpes.
The grant is a Small Business Innovation and Research grant from theNational Institute of Allergy and Infectious Diseases of the National Institutes of Health.
It will be used to developed novel adenovector-based vaccines for HSV-2, the virus responsible for most cases of genital herpes.
再简单介绍一下
第一篇
Acambis （英国公司，目前最大的一家制做疫苗的公司）这个公司已经开始研制疫苗，新药2009年应用（new drug application in 2009.
）
第二篇是GenVec 这个公司已经获批生产疫苗（herpes vaccine）
GenVec shares closed at $1.14 on the Nasdaq yesterday.
